EGFR and non-small cell lung carcinoma: Consistent with this notion, ALK+ NSCLC patients treated with even just one TKI have a longer OS than TKI-treated EGFR+ NSCLC patients (Figure 3, Table 2), and survival has generally been longer in trials of ALK inhibitors compared to trials of EGFR inhibitors (for example median OS was > 45 months in the Profile 1014 trial of the first-generation ALK inhibitor crizotinib [49] vs. 28 months in the LUX-Lung-3 study of the second-generation EGFR inhibitor afatinib [50]).